Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2022 Earnings Call Transcript

Tony Marrs: Yes. So I’ll start. Hi, David, I’ll start with the glucagon market question. As we talked about last quarter, what’s really happened is that some competitors have dropped out of the market. And so it’s given us the opportunity to expand our share of the market as long as we can meet it. That’s why the expansion of the capacity was so important. The market that we were originally marketing it in, and then now with the diagnostic aid market also seeing competitors drop out of it all, it also allows us that opportunity as well. So as we’ve said, we think of it as a way to expand our current market, or basically, we think of it as doubling our capacity and being able to lead both the diagnostic side as well as the other side that we were already doing. Vasopressin?

Dan Dischner: Vasopressin, we picked up a little bit of market share over the last quarter. And so we’re it’s still not as big a product as we thought it might be a year-ago, but it’s a product that did grow from the third to the fourth quarter. And because we only had it for half a year, we’ll have a full-year of sales, and every quarter should be higher than it was this quarter. So there’s definitely growth. That’s why that one is a growth driver. Even though it’s not a large product, it’s still going to contribute to that growth. And I think the third question was on 007.

David Amsellem: Correct. Yes.

Dan Dischner: Yes. So 007, yes, that’s going to be a P4 filing. Hard to say about litigation, but that’s always a possibility. And 027 that we have a planned filing for this quarter is a relatively small product. So of those two products, the 018 and the 027 that we’ve adjusted our presentation to show there that total $3 billion, the vast majority of the sales go to the 018. And both of them are planned to be filed in Q2.

David Amsellem: Terrific, thank you.

Dan Dischner: 007 and 027 — 007 and 027, not 018, just to clarify.

David Amsellem: Yes, got it. Thank you.

Operator: Thank you. There are no further questions in the queue. I’d like to hand the floor back over to management for any closing comments.

Dan Dischner: Yes. I want to thank everybody for joining us today. 2023 remains on track for two to four approvals. We remain optimistic about our opportunity to further grow the Glucagon market, thanks to an increase in capacity in addition to seeing further advancement in our pipeline. We look forward to updating you on our next call. Thank you.

Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.